

**NEW**



xTAG<sup>®</sup> Cystic Fibrosis 39 Kit v2  
xTAG<sup>®</sup> Cystic Fibrosis 60 Kit v2  
The broadest choice in  
CFTR mutation coverage

**Luminex**<sup>®</sup>

## Choose your assay. Choose your coverage

**xTAG® Cystic Fibrosis (CFTR) 39 Kit v2\***

ΔF508	A455E	R1162X	1078delT	1898+5G>T
ΔI507	1717-1G>A	3659delC	394delTT	2183AA>G
G542X	R560T	3849+10kbC>T	Y122X	2307insA
G85E	R553X	W1282X	R347H	Y1092X
R117H	G551D	N1303K	V520F	M1101K
621+1G>T	1898+1G>A	5/7/9T	A559T	S1255X
711+1G>T	2184delA	F508C	S549N	3876delA
R334W	2789+5G>A	I507V	S549R	3905insT
R347P	3120+1G>A	I506V		

**ACMG recommended mutations<sup>1</sup>**  
<sup>1</sup> Genet Med. 2004 Sep-Oct; 6(5):387-91.

+

**xTAG® Cystic Fibrosis (CFTR) 60 Kit v2\***

CFTR del2,3	2055del9>A
W1089X	S1196X
1677delTA	935delA
D1152H	2143delT
R1158X	K710X
G178R	G330X
3791delC	Q890X
L206W	R1066C
E60X	3199del6
R75X	406-1G>A
	Q493X

**Broad Ethnic Coverage**

**16 most common additional mutations recommended mutations covered**  
Accuracy of 100% for genotyping information used for carrier and newborn screening

List of mutations or variants identified in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene.  
\*For In Vitro Diagnostics Use Only.

Ethnic Group	Incidence of CF*	Carrier Frequency*	ACMG* RECOMMENDED MUTATIONS ONLY	CF MUTATION DETECTION RATE (%)*	
				xTAG® Cystic Fibrosis (CFTR) 39 Kit v2	xTAG® Cystic Fibrosis (CFTR) 60 Kit v2
Caucasian	1 in 3,200	1 in 25	88.3	89.7	90.6
Hispanic Americans	1 in 9,500	1 in 46	71.7	73.4	83.7
African Americans	1 in 15,300	1 in 65	64.5	68.6	72.5
Ashkenazi Jewish	1 in 3,300	1 in 25	94.0	94.0	95.9
Asian American	1 in 32,100	1 in 90	48.9	54.5	54.5

\* Data collected from the following references: Watson et al. (2004) Genet Med 6(5):387-91.; Richards et al. (2002) Genet Med 4(5):379-391.; Bobadilla et al. (2002) Human Mutat 19:575-606.; Heim et al. (2001) Genet Med 3:168-76.; Sugarman et al. (2004) Genet Med 6:392-99.; Organ et al. (2001) Genet Testing 5:47-52.; Wong et al. (2001) Human Mutat 18:296-307.; Alder et al. Human Mutat 2004 MIB #752; Shriver et al. (2005) JMD 7:289-99.

### The benefits of xTAG® Cystic Fibrosis Assays:

**Comprehensive:** Most comprehensive mutation coverage, including ACMG/ACOG recommended panel.

**Flexibility:** Mutation panel selection through the software.

**Confidence:** Second generation of IVD assay with 100% overall Accuracy and >99% Precision.

**Ease of Use:** Streamlined protocol with minimal hands-on time. All ancillary reagents and enzymes included.

**Cost-effective:** Multiplex genotyping - No reflex testing necessary.

Kit	Catalog #
xTAG Cystic Fibrosis (CFTR) 39 kit v2	I027C0231
xTAG Cystic Fibrosis (CFTR) 60 kit v2	I024C0181

US-IVD products

For more Information, visit the Luminex website at [www.luminexcorp.com](http://www.luminexcorp.com).

For sales and product information, call 1-800-593-2370 or email [info@luminexcorp.com](mailto:info@luminexcorp.com)

**UNITED STATES**  
Luminex Corporation  
Austin, Texas  
Tel: 512.219.8020  
Fax: 512.219.5195

**CANADA**  
Luminex Molecular Diagnostics  
Toronto, Ontario  
Tel: 416.593.4323  
Fax: 416.593.1066

**EUROPE**  
Luminex B.V.  
Oosterhout, The Netherlands  
Tel: +31.162.408333  
Fax: +31.162.408337

**CHINA**  
Luminex Shanghai Trading Co.  
Shanghai, China  
Tel: +21.616.50809  
Fax: +21.616.50811

**JAPAN**  
Luminex Japan Corporation, Ltd.  
Tokyo, Japan  
Tel: +81.3.5545.7440  
Fax: +81.3.5545.0451

**AUSTRALIA**  
BSD Robotics, A Luminex Company  
Brisbane, Queensland  
Tel: +61.7.3273.0273  
Fax: +61.7.3273.0274

[www.luminexcorp.com](http://www.luminexcorp.com)

[info@luminexcorp.com](mailto:info@luminexcorp.com)